Palvella Therapeutics
PVLA
81 hedge funds and large institutions have $82.2M invested in Palvella Therapeutics in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 7 closing their positions.
0.03% less ownership
Funds ownership: 0.75% → 0.72% (-0.03%)
2% less capital invested
Capital invested by funds: $83.6M → $82.2M (-$1.4M)
1% less funds holding
Funds holding: 82 → 81 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$734K |
| 2 |
Cerity Partners
New York
|
+$492K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$396K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$350K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$1.79M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.43M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.16M |
| 4 |
Renaissance Technologies
New York
|
-$261K |
| 5 |
Millennium Management
New York
|
-$235K |
PVLA Hedge Fund Activity: Q1 2021 in Review
81 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2021, worth a combined $82.2M — down 1.7% from $83.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PVLA and 6 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 22 added.
The largest buyer was Wells Fargo, adding an estimated $734K. The largest seller was Woodline Partners, cutting an estimated $1.79M.
- 81 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2021, down from 82 in Q4 2020.
- Funds reported $82.2M of Palvella Therapeutics stock for Q1 2021, down 1.7% quarter-over-quarter.
- 6 funds opened new Palvella Therapeutics positions in Q1 2021 and 7 closed out, a net change of -1 holder.
- The largest Palvella Therapeutics buyer in Q1 2021 was Wells Fargo, an estimated $734K added.
- The largest Palvella Therapeutics seller in Q1 2021 was Woodline Partners, an estimated $1.79M sold.
Based on aggregated 13F filings for Q1 2021.